Surging demand for metabolic disease therapeutics has created unprecedented strain on global peptide manufacturing networks, prompting aggressive capital investments in synthetic chemistry infrastructure.
Upstream Raw Material Bottlenecks Persist
While facility footprints are expanding, suppliers of specialized amino acid building blocks and automated synthesizer equipment report order backlogs extending into late 2026, posing short-term risks to global inventory stability.